Clinical Trial Update: A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing long-term safety and efficacy of epoetin alfa for correcting anemia in patients on early hemodialysis; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Kidney Failure, Chronic, Anemia | Phase 3 | Status: COMPLETED